COLLEGEVILLE, Pennsylvania, May 7 /PRNewswire/ --
-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease --
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13*, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein), which was submitted on March 31. Priority review designation is given to products that, if approved, would be a significant therapeutic or public health advance. Based on this designation, Wyeth expects a regulatory decision within six months.